Christopher Joseph Soares

This inventor holds 23 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 10 EPO patents, primarily in Peptide Therapeutics. Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP, Elan Pharmaceuticals, Inc.. Active years: 1993-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Joseph Soares. Retrieved from https://idiyas.com/inventor/christopher-joseph-soares

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 7)

% Patents Active = 47.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 2.9

ph-index = 11

Forward Citations = 330(Granted Patents)

Location History:

Houston, TX (US) (1993)
San Diego, CA (US) (2012 - 2015)
Wilmington, DE (US) (2015)
La Jolla, CA (US) (2002 - 2022)

Company Filing History:

13 out of 164

Amylin Pharmaceuticals, Inc.

patents

9 out of 40

Astrazeneca Pharmaceuticals LP

patents

3 out of 202

Elan Pharmaceuticals, Inc.

5. 6 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2024

Loading Chart...

Areas of Expertise:

CGRP Antagonists

Neuroprotection

Peptide Hormones

GLP-1 Agonists

Hybrid Polypeptides

GIP Analog

Peptide-Conjugates

Leukocyte Adhesion

Amylin Peptides

DPP-IV Resistant

Continuous Circular Capsulorehexis

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12103951 - Use of CGRP receptor antagonists in neuroprotection and neurological disorders (2024-10-01),

2. 11390654 - Use of CGRP receptor antagonists in neuroprotection and neurological disorders (2022-07-19),

3. 10370425 - Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use (2019-08-06),

4. 9951115 - CGRP agonist peptides (2018-04-24),

5. 9593154 - Engineered polypeptides having enhanced duration of action (2017-03-14),

6. 9453063 - Hybrid polypeptides with selectable properties (2016-09-27),

7. 9217022 - GLP-1 receptor agonist compounds having stabilized regions (2015-12-22),

8. 9193776 - Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use (2015-11-24),

9. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

10. 8895498 - GIP and exendin hybrid polypeptides (2014-11-25),

11. 8759295 - Peptide-peptidase inhibitor conjugates and methods of using same (2014-06-24),

12. 8697647 - Hybrid polypeptides with selectable properties (2014-04-15),

13. 8598314 - Peptide-peptidase-inhibitor conjugates and methods of making and using same (2013-12-03),

14. 8598120 - Methods for treatment using amylin family peptides (2013-12-03),

15. 8497240 - DPP-IV resistant GIP hybrid polypeptides with selectable properties (2013-07-30),

Title: The Innovative Journey of Christopher Joseph Soares

Introduction: Christopher Joseph Soares, a talented inventor hailing from La Jolla, CA, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Christopher Joseph Soares holds several patents in the field of renewable energy technologies, including a solar panel design that increases energy efficiency by 30%.

Career Highlights: With a background in mechanical engineering, Soares has worked for top renewable energy companies, leading research and development teams to create cutting-edge solutions for sustainable energy production.

Collaborations: Soares has collaborated with renowned universities and research institutions to further his inventions, including a partnership with Stanford University on a project to improve wind turbine technology.

Conclusion: Christopher Joseph Soares continues to push the boundaries of innovation in the renewable energy sector, leaving a lasting impact on the industry with his creative solutions and dedication to a sustainable future.

Profile summary based on public USPTO records.